Has the FDA’s ruling on direct-to-consumer genetic testing given power to the people?

The US Food and Drug Administration announced on 6 April, 2017 that it has “allowed marketing of 23andMe Personal Genome Service Genetic Health Risk (GHR) tests for 10 diseases or conditions. These are the first direct-to-consumer (DTC) tests authorized by the FDA that provide information on an individual’s genetic predisposition to certain medical diseases or […]

Which pharma companies are ready for diagnostic integration in 2017?

The regular Pharma Readiness reports produced by Diaceutics aim to capture a snapshot of the diagnostic and precision medicine industries at certain times in a fast-evolving landscape. Pharma Readiness for Diagnostic Integration 2017 is no exception and discusses such vital topics as: Trends, best practice and preferred organizational styles in diagnostics (Dx) and precision medicine […]